Related Experiment Video
Updated: May 18, 2026
08:40
Surgical Technique of the 3-Dimensional-printed Personalized Hip Implant for the Treatment of Canine Hip Dysplasia
Published on: April 19, 2024
[Glucosamine preparations on the Belgian market: a comparative study].
1Service de Contrôte des Médicaments, APB.
Journal De Pharmacie De Belgique
|September 18, 2012
Summary
This study assessed glucosamine supplements and medicine for quality. One medicine met all standards, but three food supplements failed disintegration and glucosamine content tests.
Area of Science:
- Pharmacology
- Analytical Chemistry
- Nutritional Science
Background:
- Glucosamine is a popular dietary supplement for joint health.
- Ensuring the quality and efficacy of glucosamine products is crucial for consumer safety.
- Regulatory standards for food supplements can differ from pharmaceutical products.
Purpose of the Study:
- To evaluate the quality of glucosamine-containing food supplements and one medicine.
- To assess compliance with pharmacopeial standards for disintegration and glucosamine content.
- To identify potential quality variations in the glucosamine market.
Main Methods:
- Analysis of 14 food supplements and 1 medicine containing glucosamine.
- Performed tests for uniformity of mass and dosage units.
- Utilized High-Performance Liquid Chromatography with Evaporative Light Scattering Detection (HPLC-ELSD) for identification and assay.
Main Results:
- The medicinal product met all specified quality requirements.
- Three food supplements failed to meet disintegration standards (product 7).
- Three food supplements failed to meet glucosamine content standards (products 11 and 13).
Conclusions:
- While the tested medicine demonstrated adequate quality, several glucosamine food supplements exhibited significant quality deficiencies.
- Variability in disintegration and glucosamine content highlights the need for stringent quality control in supplement manufacturing.
- Consumers should be aware of potential inconsistencies in glucosamine supplement quality.
Related Concept Videos
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
01:19Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
01:13Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
01:23Glycosaminoglycans
Glycosaminoglycans (GAGs), also known as mucopolysaccharides, are long and linear polymers comprising of specific repeating disaccharides - the amino sugar that can be N-acetylglucosamine or N-acetylgalactosamine, and a uronic acid that is usually glucuronic acid or iduronic acid.
GAGS are found in the extracellular matrix of vertebrates, invertebrates, and bacteria. Due to their polar nature they attract water, and serve as excellent lubricants or shock absorbers in an animal body.
Hyaluronic...
GAGS are found in the extracellular matrix of vertebrates, invertebrates, and bacteria. Due to their polar nature they attract water, and serve as excellent lubricants or shock absorbers in an animal body.
Hyaluronic...
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...